TABLE 1.
Comparison of baseline characteristics and outcomes between KTR with COVID-19 who received anti-spike monoclonal antibody treatment as outpatients and those who did not
| Parameter | Unmatched cohort |
Propensity score–matched cohort |
||||
|---|---|---|---|---|---|---|
| mAb, n = 20 | No mAb, n = 75 | p-value | mAb, n = 18 | No mAb, n = 18 | p-value | |
| Demographics | ||||||
| Age (years) | 55.0 (31–79) | 58 (38–78) | .691 | 56.0 (43–67.5) | 55.5 (40.5–62.5) | 0.501 |
| Men | 15 (75.0) | 45 (60.0) | .299 | 13 (72.2) | 14 (77.8) | >0.999 |
| Black | 1 (5.0) | 14 (18.7) | .181 | 1 (5.6) | 3 (16.7) | 0.603 |
| Hispanic | 3 (15.0) | 25 (33.3) | .167 | 3 (16.7) | 1 (5.6) | 0.603 |
| Black or Hispanic | 4 (20.0) | 39 (52.0) | .010 | 4 (22.2) | 4 (22.2) | >0.999 |
| BMI, kg/m2 | 30.4 (26.5–35.3) | 28.2 (24.4–33.9) | .333 | 29.0 (25.9–34.3) | 26.7 (23.6–32.9) | 0.339 |
| Time after transplant (months) | 44.5 (16.8–176.3) | 50.0 (26.0–132.0) | .635 | 44.5 (18.3–148.0) | 42.5 (22.0–89.0) | 0.650 |
| Comorbidities | ||||||
| Hypertension | 19 (95.0) | 65 (86.7) | .448 | 17 (94.4) | 16 (88.9) | >0.999 |
| CKD | 11 (55.0) | 59 (78.7) | .046 | 10 (55.6) | 11 (61.1) | >0.999 |
| CHF | 1 (5.0) | 9 (12.0) | .683 | 1 (5.6) | 1 (5.6) | >0.999 |
| Diabetes | 7 (35.0) | 32 (42.7) | .615 | 6 (33.3) | 5 (27.8) | >0.999 |
| Lung disease | 4 (20.0) | 15 (20.0) | >.999 | 3 (16.7) | 3 (16.7) | >0.999 |
| Baseline immunosuppression | ||||||
| 3-drug regimen | 18 (90.0) | 60 (80.0) | .512 | 16 (88.9) | 17 (94.4) | >0.999 |
| 2-drug regimen | 2 (10.0) | 13 (17.3) | .730 | 2 (11.1) | 1 (5.6) | >0.999 |
| 1-drug regimen | 0 (0.0) | 2 (2.7) | >.999 | 0 (0.0) | 0 (0.0) | >0.999 |
| Calcineurin/mTOR inhibitor | 19 (95.0) | 73 (97.3) | .512 | 17 (94.4) | 17 (94.4) | >0.999 |
| Tacrolimus | 15 (75.0) | 60 (80.0) | .758 | 13 (72.2) | 15 (83.3) | 0.691 |
| Sirolimus | 2 (10.0) | 8 (10.7) | >.999 | 2 (11.1) | 1 (5.6) | >0.999 |
| Cyclosporine | 2 (10.0) | 3 (4.0) | .282 | 2 (11.1) | 1 (5.6) | >0.999 |
| Antimetabolite | 18 (90.0) | 60 (80.0) | .512 | 16 (88.9) | 18 (100.0) | >0.999 |
| Mycophenolate | 15 (75.0) | 53 (70.7) | .787 | 13 (72.2) | 16 (88.9) | 0.402 |
| Azathioprine | 3 (15.0) | 7 (9.3) | .434 | 3 (16.7) | 2 (11.1) | >0.999 |
| Held or decreaseda | 8 (44.4) | 43 (71.6) | .047 | 7 (43.8) | 10 (58.8) | 0.505 |
| Prednisone | 20 (100.0) | 73 (97.3) | >.999 | 17 (94.4) | 18 (100.0) | >0.999 |
| Outcomes | ||||||
| Hospitalization or ER visit | 3 (15.0) | 57 (76.0) | <.001 | 3 (16.7) | 10 (55.6) | 0.035 |
| Mechanical ventilation | 0 (0.0) | 13 (17.3) | .063 | 0 (0.0) | 1 (5.6) | >0.999 |
| In-hospital death or hospice | 0 (0.0) | 8 (10.7) | .197 | 0 (0.0) | 0 (0.0) | >0.999 |
Note: Data are presented as mean median (interquartile range [IQR]) for continuous variables and number (%) for categorical variables. Two-sided p-values <.05 are bold.
Abbreviations: BMI, body mass index; CHF, congestive heart failure; CKD, chronic kidney disease; ER, emergency room; KTR, kidney transplant recipients; mTOR, mammalian target of rapamycin.
a
Percentage refers to the number of KTR who were taking an antimetabolite at baseline.